MX2010003713A - Vacunas de citomegalovirus y metodos de produccion. - Google Patents

Vacunas de citomegalovirus y metodos de produccion.

Info

Publication number
MX2010003713A
MX2010003713A MX2010003713A MX2010003713A MX2010003713A MX 2010003713 A MX2010003713 A MX 2010003713A MX 2010003713 A MX2010003713 A MX 2010003713A MX 2010003713 A MX2010003713 A MX 2010003713A MX 2010003713 A MX2010003713 A MX 2010003713A
Authority
MX
Mexico
Prior art keywords
methods
production
cytomegalovirus
vaccines
cytomegalovirus vaccines
Prior art date
Application number
MX2010003713A
Other languages
English (en)
Spanish (es)
Inventor
Thomas Shenk
Dai Wang
Original Assignee
Univ Princeton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Princeton filed Critical Univ Princeton
Publication of MX2010003713A publication Critical patent/MX2010003713A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16161—Methods of inactivation or attenuation
    • C12N2710/16164—Methods of inactivation or attenuation by serial passage

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2010003713A 2007-10-10 2008-10-10 Vacunas de citomegalovirus y metodos de produccion. MX2010003713A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99842607P 2007-10-10 2007-10-10
PCT/US2008/079494 WO2009049138A1 (en) 2007-10-10 2008-10-10 Cytomegalovirus vaccines and methods of production

Publications (1)

Publication Number Publication Date
MX2010003713A true MX2010003713A (es) 2010-08-02

Family

ID=40549581

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003713A MX2010003713A (es) 2007-10-10 2008-10-10 Vacunas de citomegalovirus y metodos de produccion.

Country Status (15)

Country Link
US (2) US9439960B2 (enExample)
EP (1) EP2200645B1 (enExample)
JP (1) JP5409638B2 (enExample)
KR (1) KR20100084627A (enExample)
CN (1) CN101820906B (enExample)
AU (1) AU2008310713B2 (enExample)
BR (1) BRPI0818656A2 (enExample)
CA (1) CA2701727C (enExample)
IL (1) IL204850A0 (enExample)
MX (1) MX2010003713A (enExample)
NZ (1) NZ584459A (enExample)
RU (1) RU2491340C2 (enExample)
SG (1) SG185291A1 (enExample)
WO (1) WO2009049138A1 (enExample)
ZA (1) ZA201002216B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9439960B2 (en) 2007-10-10 2016-09-13 The Trustees Of Princeton University Cytomegalovirus vaccines and methods of production
US8580276B2 (en) 2009-06-05 2013-11-12 City Of Hope Genetically stable recombinant modified vaccinia ankara (rMVA) vaccines and methods of preparation thereof
TWI570240B (zh) 2011-09-09 2017-02-11 默沙東公司 作為細胞巨大病毒疫苗之條件式複製ｃｍｖ
EP2831285B1 (en) * 2012-03-27 2019-10-30 Variation Biotechnologies Inc. Methods for detection of anti-cytomegalovirus neutralizing antibodies
MX378747B (es) 2012-07-06 2025-03-10 Glaxosmithkline Biologicals S A Star Complejos de proteínas de citomegalovirus.
AU2013293570B2 (en) 2012-07-27 2019-05-23 City Of Hope An MVA vaccine for delivery of a UL128 complex and preventing CMV infection
US9395369B2 (en) 2012-10-19 2016-07-19 Regents Of The University Of Minnesota Guinea pig cytomegalovirus (CIDMTR strain)
CN103937871B (zh) * 2013-01-23 2019-07-23 上海市东方医院 Srrp35基因和表达产物在癌症诊断与治疗中的应用
US20160289303A1 (en) * 2013-11-15 2016-10-06 President And Fellows Of Harvard College Methods and compositions for the treatment of hcmv
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
EP3601543A4 (en) * 2017-03-30 2021-01-27 Merck Sharp & Dohme Corp. ADDING NUCLEASES DIRECTLY TO CELL CULTURE TO FACILITATE DIGESTION AND RELEASE OF HOST CELL NUCLEIC ACIDS
CA3060019A1 (en) * 2017-04-19 2018-10-25 Glaxosmithkline Biologicals Sa Modified cytomegalovirus proteins and stabilized complexes
WO2019089410A1 (en) * 2017-11-01 2019-05-09 Merck Sharp & Dohme Corp. Stable formulations of cytomegalovirus
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
TWI810589B (zh) 2020-06-21 2023-08-01 美商輝瑞股份有限公司 人巨細胞病毒糖蛋白Ｂ（ｇＢ）多肽

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959466A (en) 1974-04-15 1976-05-25 The Wistar Institute Highly attenuated cytomegalovirus vaccine and production thereof
US4058598A (en) 1974-10-18 1977-11-15 Harold Stern Cytomegalovirus attenuation method and vaccine
US6471965B1 (en) 1994-07-27 2002-10-29 Bio-Virus Research Incorporated Vaccine containing whole killed herpes viruses to prevent development of atherosclerotic plaque
DE10144906B4 (de) * 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
WO2005012545A2 (en) 2003-07-25 2005-02-10 The Regents Of The University Of California Cytomegalovirus gene function and methods for developing antivirals, anti-cmv vaccines, and cmv-based vectors
CA2654563A1 (en) * 2006-06-07 2007-12-21 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
US9439960B2 (en) 2007-10-10 2016-09-13 The Trustees Of Princeton University Cytomegalovirus vaccines and methods of production

Also Published As

Publication number Publication date
RU2491340C2 (ru) 2013-08-27
US20170014504A1 (en) 2017-01-19
AU2008310713B2 (en) 2012-06-14
KR20100084627A (ko) 2010-07-27
BRPI0818656A2 (pt) 2015-04-14
EP2200645A4 (en) 2012-07-11
JP2011500592A (ja) 2011-01-06
CN101820906A (zh) 2010-09-01
EP2200645A1 (en) 2010-06-30
CA2701727C (en) 2016-12-13
CN101820906B (zh) 2015-04-22
US10300130B2 (en) 2019-05-28
NZ584459A (en) 2012-06-29
US9439960B2 (en) 2016-09-13
US20100285059A1 (en) 2010-11-11
IL204850A0 (en) 2010-11-30
WO2009049138A1 (en) 2009-04-16
ZA201002216B (en) 2011-06-29
SG185291A1 (en) 2012-11-29
JP5409638B2 (ja) 2014-02-05
CA2701727A1 (en) 2009-04-16
AU2008310713A1 (en) 2009-04-16
RU2010117741A (ru) 2011-11-20
EP2200645B1 (en) 2016-01-27

Similar Documents

Publication Publication Date Title
MX2010003713A (es) Vacunas de citomegalovirus y metodos de produccion.
MX2021006342A (es) Mutantes de virus de influenza y usos para los mismos.
WO2005042728A3 (en) Immortalized avian cell lines for virus production
HUE045487T2 (hu) B7-H3-ra reaktív antitestek, immunológiailag aktív fragmenseik és alkalmazásaik
NZ623113A (en) Combined use of gdf traps and erythropoietin receptor activators to increase red blood cell levels
WO2009155535A3 (en) Compositions, methods and kits for eliciting an immune response
MX2012011774A (es) Polipeptidos que tienen actividad de glucoamilasa y polinucleotidos que codifican los mismos.
AU2014203512B2 (en) Recombinant virus-like particles encoded by multi-gene vector
MY170720A (en) Antibody formulations
WO2011109833A3 (en) Induced dendritic cell compositions and uses thereof
WO2011156654A3 (en) Pathways characterization of cells
MX2015011781A (es) Medio de cultivo celular y metodos de produccion de anticuerpos.
WO2009099877A3 (en) Closterovirus vectors and methods
PH12013500500A1 (en) Fused heteroaryls and their uses
EA201001045A1 (ru) Модифицированный вирус гриппа
WO2011133727A3 (en) Anti-viral compounds
MX346364B (es) Particulas porosas de oxido inorganico y metodos para preparar y utilizar los mismos.
WO2011160021A3 (en) Fullerene derivatives and photovoltaic cell containing them
WO2013030176A3 (en) Live attenuated influenza virus
WO2011133707A3 (en) Anti-viral compounds
WO2011057254A3 (en) Simian adenoviral vector-based vaccines
WO2011006145A3 (en) Compositions and methods for mammalian genetics and uses thereof
WO2006063053A3 (en) Methods of producing influenza vaccine compositions
WO2012094193A3 (en) Methods for enhancing the delivery of gene-transduced cells
MX2012007283A (es) Composiciones para vacunas.

Legal Events

Date Code Title Description
FG Grant or registration